Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer

被引：180

作者：

Tugues, Sonia ^{[1
]}

Koch, Sina ^{[1
]}

Gualandi, Laura ^{[1
]}

Li, Xiujuan ^{[1
]}

Claesson-Welsh, Lena ^{[1
]}

机构：

[1] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden

来源：

MOLECULAR ASPECTS OF MEDICINE | 2011年 / 32卷 / 02期

关键词：

VEGFA; VEGF receptors; Neuropilin; Anti-angiogenesis; Sunitinib; Sorafenib; Bevacizumab; TYROSINE KINASE INHIBITOR; RENAL-CELL CARCINOMA; BEVACIZUMAB PLUS IRINOTECAN; LYMPH-NODE METASTASIS; TUMOR-GROWTH; HEPARIN-BINDING; BONE-MARROW; FACTOR-B; VEGF-A; ANTIANGIOGENIC THERAPY;

D O I：

10.1016/j.mam.2011.04.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Vascular endothelial growth factors (VEGFs) are critical regulators of vascular and lymphatic function during development, in health and in disease. There are five mammalian VEGF ligands and three VEGF receptor tyrosine kinases. In addition, several VEGF co-receptors that lack intrinsic catalytic activity, but that indirectly modulate the responsiveness to VEGF contribute to the final biological effect. This review describes the molecular features of VEGFs. VEGFRs and co-receptors with focus on their role in the treatment of cancer. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：88 / 111

页数：24

共 329 条

[61] THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].

DEVRIES, C ;

ESCOBEDO, JA ;

UENO, H ;

HOUCK, K ;

FERRARA, N ;

WILLIAMS, LT .

SCIENCE, 1992, 255 (5047) :989-991

[62] Brivanib alaninate for cancer [J].

Diaz-Padilla, Ivan ;

Siu, Lillian L. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (04) :577-586

[63] Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation [J].

Dikov, MM ;

Ohm, JE ;

Ray, N ;

Tchekneva, EE ;

Burlison, J ;

Moghanaki, D ;

Nadaf, S ;

Carbone, DP .

JOURNAL OF IMMUNOLOGY, 2005, 174 (01) :215-222

[64] PURIFICATION AND CHARACTERIZATION OF A NATURALLY-OCCURRING VASCULAR ENDOTHELIAL GROWTH-FACTOR PLACENTA GROWTH-FACTOR HETERODIMER [J].

DISALVO, J ;

BAYNE, ML ;

CONN, G ;

KWOK, PW ;

TRIVEDI, PG ;

SODERMAN, DD ;

PALISI, TM ;

SULLIVAN, KA ;

THOMAS, KA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (13) :7717-7723

[65] Cardiovascular failure in mouse embryos deficient in VEGF receptor-3 [J].

Dumont, DJ ;

Jussila, L ;

Taipale, J ;

Lymboussaki, A ;

Mustonen, T ;

Pajusola, K ;

Breitman, M ;

Alitalo, K .

SCIENCE, 1998, 282 (5390) :946-949

[66] Antiangiogenic and antimetastatic properties of Neovastat (Æ-941), an orally active extract derived from cartilage tissue [J].

Dupont, É ;

Falardeau, P ;

Mousa, SA ;

Dimitriadou, V ;

Pepin, MC ;

Wang, TQ ;

Alaoui-Jamali, MA .

CLINICAL & EXPERIMENTAL METASTASIS, 2002, 19 (02) :145-153

[67] Discovery of vascular permeability factor (VPF) [J].

Dvorak, HF .

EXPERIMENTAL CELL RESEARCH, 2006, 312 (05) :522-526

[68] Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy [J].

Dvorak, HF .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4368-4380

[69] Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis [J].

Ebos, John M. L. ;

Lee, Christina R. ;

Cruz-Munoz, William ;

Bjarnason, Georg A. ;

Christensen, James G. ;

Kerbel, Robert S. .

CANCER CELL, 2009, 15 (03) :232-239

[70]

Eggert A, 2000, CLIN CANCER RES, V6, P1900

← 2 3 4 5 6 7 8 9 10 11 →